The radiobiology of laser-driven particle beams: focus on sub-lethal responses of normal human cells
The radiobiology of laser-driven particle beams: focus on sub-lethal responses of normal human cells
复制标题
DOI：
10.1088/1748-0221/12/03/c03084
复制
发表时间：
2017-03-01
影响因子：
1.3
通讯作者：
Tramontana, A.
中科院分区：
文献类型：
--
作者：
Manti, L.;Perozziello, F. M.;Tramontana, A.
加速质子束在治疗癌症方面已经变得越来越普遍。为了减少粒子加速器的成本和尺寸，基于激光-等离子体相互作用的光学离子加速技术作为一种可能的替代方案进行了开创性的研究。激光与物质的相互作用可以产生极高剂量率的极脉冲粒子爆发(>；=10(9)Gy/S)，大大超过目前用于传统质子治疗的粒子爆发。由于电离辐射的生物效应受到DNA损伤事件时空分布的强烈影响，这种射束前所未有的物理特征可能会以未知的程度改变细胞和组织的辐射敏感性。因此，激光产生的颗粒的临床应用需要对其放射生物学效果进行彻底的评估。到目前为止，大多数研究要么使用啮齿动物细胞系，要么集中在局部肿瘤控制的癌细胞杀伤作为放射治疗的主要目标。相反，关于亚致死细胞效应的数据很少，与正常组织完整性和继发性癌症(如细胞过早衰老)相关。在这里，我们讨论超高剂量率放射生物学，并提供在位于法国欧洲激光实验室的LULI PICO2000设施中，激光加速质子照射后在正常人细胞中获得的初步数据。
Accelerated proton beams have become increasingly common for treating cancer. The need for cost and size reduction of particle accelerating machines has led to the pioneering investigation of optical ion acceleration techniques based on laser-plasma interactions as a possible alternative. Laser-matter interaction can produce extremely pulsed particle bursts of ultra-high dose rates (>= 10(9) Gy/s), largely exceeding those currently used in conventional proton therapy. Since biological effects of ionizing radiation are strongly affected by the spatio-temporal distribution of DNA-damaging events, the unprecedented physical features of such beams may modify cellular and tissue radiosensitivity to unexplored extents. Hence, clinical applications of laser-generated particles need thorough assessment of their radiobiological effectiveness. To date, the majority of studies have either used rodent cell lines or have focussed on cancer cell killing being local tumour control the main objective of radiotherapy. Conversely, very little data exist on sub-lethal cellular effects, of relevance to normal tissue integrity and secondary cancers, such as premature cellular senescence. Here, we discuss ultra-high dose rate radiobiology and present preliminary data obtained in normal human cells following irradiation by laser-accelerated protons at the LULI PICO2000 facility at Laser Lab Europe, France.